Table 10.

IGF2BP2 and IGFBP3 haplotype frequencies (%) in patients and controls and risk of NSCLC

Haplotypes	Cases (n=1042)		Controls (n=2,060)		Crude OR (95% CI)	P-value
	n	%	n	%
Ars1470579Crs2270628Grs3110697Grs4402960Grs6953668	444	42.65	888	43.21	Reference	–
Ars1470579Crs2270628Ars3110697Grs4402960Grs6953668	150	14.41	282	13.72	1.06 (0.85–1.34)	0.596
Crs1470579Crs2270628Grs3110697Trs4402960Grs6953668	133	12.78	304	14.79	0.88 (0.69–1.11)	0.262
Ars1470579Trs2270628Grs3110697Grs4402960Grs6953668	137	13.16	225	12.41	1.22 (0.96–1.55)	0.109
Crs1470579Crs2270628Ars3110697Trs4402960Grs6953668	47	4.51	83	4.04	1.13 (0.78–1.65)	0.516
Crs1470579Trs2270628Grs3110697Trs4402960Grs6953668	43	4.13	74	3.60	1.16 (0.78–1.72)	0.453
Ars1470579Crs2270628Ars3110697Grs4402960Ars6953668	34	3.27	56	2.73	1.21 (0.78–1.89)	0.388
Ars1470579Trs2270628Ars3110697Grs4402960Grs6953668	16	1.54	50	2.43	0.64 (0.36–1.14)	0.125
Crs1470579Crs2270628Ars3110697Trs4402960Ars6953668	12	1.15	15	0.73	1.60 (0.74–3.45)	0.226
Ars1470579Trs2270628Ars3110697Grs4402960Ars6953668	6	0.58	12	0.58	1.00 (0.37–2.68)	1.000
Crs1470579Trs2270628Ars3110697Trs4402960Grs6953668	4	0.38	11	0.54	0.73 (0.23–2.30)	0.785
Crs1470579Crs2270628Grs3110697Grs4402960Grs6953668	5	0.48	7	0.34	1.43 (0.45–4.53)	0.549
Crs1470579Trs2270628Ars3110697Trs4402960Ars6953668	3	0.29	9	0.44	0.67 (0.18–2.48)	0.761
Crs1470579Crs2270628Ars3110697Grs4402960Grs6953668	2	0.19	3	0.15	1.33 (0.22–8.01)	1.000
Ars1470579Crs2270628Ars3110697Trs4402960Grs6953668	3	0.29	2	0.10	3.00 (0.50–18.03)	0.341
Ars1470579Crs2270628Grs3110697Grs4402960Ars6953668	0	0.00	13	0.63	–	0.007
Crs1470579Trs2270628Grs3110697Grs4402960Grs6953668	0	0.00	8	0.39	–	0.058
Ars1470579Trs2270628Grs3110697Grs4402960Ars6953668	0	0.00	3	0.15	–	0.555
Crs1470579Trs2270628Grs3110697Trs4402960Ars6953668	0	0.00	3	0.15	–	0.555
Others	2	0.19	7	0.34	0.57 (0.12–2.76)	0.726

Note: Bold values are statistically significant (P<0.05).

Abbreviation: NSCLC, non-small-cell lung cancer.